“seattle-genetics” Archives

in
Entry Author Date Location
Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More 01/03/20 National
Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More 10/25/19 National
SeaGen to Seek FDA Nod After Breast Cancer Drug Hits Goals of Key Study 10/21/19 Seattle
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More 10/01/19 National
Genmab, Mirum Pharma & Fulcrum Raise $653M in Wall Street Debuts 07/18/19 National
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More 03/29/19 National
VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Clinic 10/01/18 San Diego
Unum Therapeutics IPO Raises $69M to Test Universal Cell Therapies 03/29/18 Boston
Bio Roundup: CMS Backs Cancer Tests, Right to Try Passes, AbbVie Sinks 03/23/18 National
Unum, Homology Plan IPOs, as Unum Reveals Two Patient Deaths 03/05/18 Boston
Bio Roundup: Wilson’s Warning, Amazon’s Health Biz, Moderna Cash & More 02/02/18 National
Bio Buyout Spree Continues as SeaGen Bets $614M on Cascadian Cancer Drug 01/31/18 Seattle
ASH 2017 Highlights: CAR-T Competition, Myeloma, Hemophilia & More 12/11/17 National
Bio Roundup: Barron Joins GSK, Sage Bounces Back, Valeant Dumps Addyi 11/10/17 National
Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More 06/30/17 National
Bio Roundup: Senate Trumpcare, FDA On Cancer, Alzheimer Review & More 06/23/17 National
SeaGen Ends One Leukemia Drug Trial, Stops Enrolling Three Others 06/19/17 Seattle
Mersana Plans IPO to Finance Clinical Trials for Breast Cancer Drug 06/02/17 Boston
VenBio Settles Immunomedics Litigation, SeaGen Nixes Cancer Drug Deal 05/05/17 New York
AACR Review: Biden Fired Up, Incyte Doubles Up, BMS Up And Down 04/06/17 National
Biotech Roundup: Obamacare Lite, DePinho Out, Dunsire In & More 03/10/17 National
Seattle Genetics to Resume Leukemia Drug Trials After FDA Lifts Hold 03/06/17 Seattle
VenBio-Backed Directors Wrest Control of Immunomedics Board 03/03/17 New York
Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More 02/17/17 National
Seattle Genetics Puts Up $250M for Immunomedics Cancer Drug Rights 02/10/17 Seattle
Liver Damage, Patient Deaths Lead FDA to Halt SeaGen Leukemia Trials 12/27/16 Seattle
Cepheid, Propelled By Seattle Chemists, Sells to Danaher for $4B 09/06/16 San Francisco
Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More 08/05/16 National
Biotech Roundup: Duchenne Delay, Forum’s Fate, Califf, Ionis & More 05/27/16 National
Big Bucks, Tiny Bubbles: Ex-Biogen Exec’s Exosome Startup Nabs $80M 11/17/15 Boston
Page 1 of 10 next page »